Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New evidence links inflammation to venous disease

19.11.2003


Research could lead to new diagnostic tests; safer treatments for blood clots in deep leg veins



For a medical disorder affecting more than 250,000 Americans each year, researchers don’t know much more today about what causes blood clots in veins than they did over 100 years ago. But deep vein thromboses or DVTs are a serious health problem, especially in the elderly. When blood clots form in deep leg veins, they can permanently damage the venous system or even be fatal, if a blood clot, or pulmonary embolism, travels to the lungs.

Until recently, DVT was thought to be solely a blood or vascular disorder. Now, scientists from the University of Michigan Medical School have discovered intriguing new evidence to support the idea that the development of blood clots in veins – just like blocked arteries in atherosclerosis – is an inflammatory process.


"When a blood clot develops in superficial veins of the leg – a condition called phlebitis – the redness and swelling associated with inflammation are visible," says Thomas W. Wakefield, M.D., a scientist and vascular surgeon in the U-M’s Cardiovascular Center. "When a clot forms deep inside the leg, these signs are hidden, so physicians have rarely associated DVTs with inflammation."

Working with Daniel D. Myers, DVM, MPH, an assistant professor of vascular surgery and animal medicine in the U-M Medical School, Wakefield is trying to figure out exactly what happens inside veins when a blood clot develops. In a study published in the November 2003 issue of The Journal of Vascular Surgery, he and Myers report that inflammatory molecules and immune system cells play a major role in the process.

The U-M scientists used four types of mice in the study. The first was a strain of genetically engineered mice developed by co-author Denisa D. Wagner, Ph.D, a professor of pathology at Harvard Medical School. A genetic mutation in these mice causes them to have abnormally high levels of a pro-inflammatory molecule called P-selectin circulating in their blood plasma. In previous studies, Wakefield has found that large amounts of P-selectin are expressed in the vein wall shortly after a blood clot starts to form.

A second group of mice lacked the gene required to produce P-selectin. A third group was unable to express either P-selectin or a related molecule called E-selectin. The fourth group consisted of normal controls. In all, 659 mice were involved in the research study.

Mice were surgically treated to induce thrombosis in the IVC – the major vein carrying blood from the lower body back to the heart. On the second and sixth day after surgery, U-M scientists measured the size and weight of blood clots in the IVC, examined the vein walls and took blood samples from mice in all four groups.

U-M scientists found that mice with the highest levels of P-selectin in their blood developed the largest venous blood clots and had more inflammatory cells in their vein walls. Blood from mice with high levels of P-selectin also contained microparticles – small fragments of cell membrane from degraded cells. Most of these microparticles came from immune system cells called leukocytes, but some were derived from blood platelets, which are responsible for clot initiation. Additionally, some may have come from endothelial cells lining vein walls.

"Our laboratory is the first to evaluate microparticle formation in a mouse model of DVT," Myers says. "We found that when P-selectin binds to its receptor, it seems to release these pro-coagulant microparticles, which accelerate the clot-forming process. Mice with more leukocyte-derived microparticles developed larger blood clots than mice with microparticles derived primarily from blood platelets."

Wakefield says the ultimate goal of his research is finding new ways to inhibit clot formation in his patients by using an anti-inflammatory approach, instead of relying on anticoagulants to treat DVT after it develops.

"All current blood-thinning medications can cause serious bleeding problems in patients, so there’s a need for new treatment options," he says. "The more we understand about the mechanism of DVT formation, the better our chances of finding safer ways to treat it. Just stopping inflammation alone will not inhibit thrombosis. You have to target the interaction between inflammation and thrombosis, which is why we think P-selectin or leukocyte-derived microparticles would make good therapeutic targets."

In addition to research designed to understand the complex relationship between inflammation and thrombosis, Wakefield also is conducting clinical studies to see whether microparticles or P-selectin could be used as a diagnostic marker for DVT formation in patients.

"Right now, the gold standard for diagnosis of DVT is ultrasound," Wakefield says. "We have other diagnostic tests, but none of them are accurate enough to use on their own. You have to combine them with a test such as ultrasound, which is expensive and labor-intensive. Better markers would allow us to detect the early stages of DVT development and intervene before problems develop."

The study was funded by the National Institutes of Health and Wyeth Research of Cambridge, Mass. In addition to Denisa Wagner, Ph.D., a professor of pathology and member of the Center for Blood Research at Harvard University, other research collaborators included Robert G. Schaub, Ph.D., assistant vice president of cardiovascular and metabolic diseases, Wyeth Research; Anjali Kumar, Ph.D., director of pharmacology, Critical Therapeutics in Cambridge, Mass.; U-M research associates Angela Hawley, Diana Farris, Shirley Wrobleski; and Porama Thanaporn, a U-M medical student.


Reference: The Journal of Vascular Surgery: 38 (5), pp.1075-1089 (November 2003)

Sally Pobojewski | EurekAlert!
Further information:
http://www2.med.umich.edu/prmc/media/relarch.cfm

More articles from Health and Medicine:

nachricht Correct connections are crucial
26.06.2017 | Charité - Universitätsmedizin Berlin

nachricht One gene closer to regenerative therapy for muscular disorders
01.06.2017 | Cincinnati Children's Hospital Medical Center

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Can we see monkeys from space? Emerging technologies to map biodiversity

An international team of scientists has proposed a new multi-disciplinary approach in which an array of new technologies will allow us to map biodiversity and the risks that wildlife is facing at the scale of whole landscapes. The findings are published in Nature Ecology and Evolution. This international research is led by the Kunming Institute of Zoology from China, University of East Anglia, University of Leicester and the Leibniz Institute for Zoo and Wildlife Research.

Using a combination of satellite and ground data, the team proposes that it is now possible to map biodiversity with an accuracy that has not been previously...

Im Focus: Climate satellite: Tracking methane with robust laser technology

Heatwaves in the Arctic, longer periods of vegetation in Europe, severe floods in West Africa – starting in 2021, scientists want to explore the emissions of the greenhouse gas methane with the German-French satellite MERLIN. This is made possible by a new robust laser system of the Fraunhofer Institute for Laser Technology ILT in Aachen, which achieves unprecedented measurement accuracy.

Methane is primarily the result of the decomposition of organic matter. The gas has a 25 times greater warming potential than carbon dioxide, but is not as...

Im Focus: How protons move through a fuel cell

Hydrogen is regarded as the energy source of the future: It is produced with solar power and can be used to generate heat and electricity in fuel cells. Empa researchers have now succeeded in decoding the movement of hydrogen ions in crystals – a key step towards more efficient energy conversion in the hydrogen industry of tomorrow.

As charge carriers, electrons and ions play the leading role in electrochemical energy storage devices and converters such as batteries and fuel cells. Proton...

Im Focus: A unique data centre for cosmological simulations

Scientists from the Excellence Cluster Universe at the Ludwig-Maximilians-Universität Munich have establised "Cosmowebportal", a unique data centre for cosmological simulations located at the Leibniz Supercomputing Centre (LRZ) of the Bavarian Academy of Sciences. The complete results of a series of large hydrodynamical cosmological simulations are available, with data volumes typically exceeding several hundred terabytes. Scientists worldwide can interactively explore these complex simulations via a web interface and directly access the results.

With current telescopes, scientists can observe our Universe’s galaxies and galaxy clusters and their distribution along an invisible cosmic web. From the...

Im Focus: Scientists develop molecular thermometer for contactless measurement using infrared light

Temperature measurements possible even on the smallest scale / Molecular ruby for use in material sciences, biology, and medicine

Chemists at Johannes Gutenberg University Mainz (JGU) in cooperation with researchers of the German Federal Institute for Materials Research and Testing (BAM)...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Plants are networkers

19.06.2017 | Event News

Digital Survival Training for Executives

13.06.2017 | Event News

Global Learning Council Summit 2017

13.06.2017 | Event News

 
Latest News

Touch Displays WAY-AX and WAY-DX by WayCon

27.06.2017 | Power and Electrical Engineering

Drones that drive

27.06.2017 | Information Technology

Ultra-compact phase modulators based on graphene plasmons

27.06.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>